Literature DB >> 18332214

Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.

Hakim Echchannaoui1, Matteo Bianchi, David Baud, Martine Bobst, Jean-Christophe Stehle, Denise Nardelli-Haefliger.   

Abstract

Cervical cancer, the second leading cause of cancer deaths in women, is the consequence of high-risk human papillomavirus (HPV) infections. Toward the development of therapeutic vaccines that can induce both innate and adaptive mucosal immune responses, we analyzed intravaginal (ivag) vaccine delivery of live attenuated Salmonella enterica serovar Typhimurium expressing HPV16L1 as a model antigen. Innate immune responses were examined in cervicovaginal tissues by determining gene expression patterns by microarray analysis using nylon membranes imprinted with cDNA fragments coding for inflammation-associated genes. At 24 h, a wide range of genes, including those for chemokines and Th1- and Th2-type cytokine and chemokine receptors were up-regulated in mice ivag immunized with Salmonella compared to control mice. However, the majority of transcripts returned to their steady-state levels 1 week after immunization, suggesting a transient inflammatory response. Indeed, cervicovaginal histology of immunized mice showed a massive, but transient, infiltration of macrophages and neutrophils, while T cells were still increased after 7 days. Ivag immunization also induced humoral and antitumor immune responses, i.e., serum and vaginal anti-HPV16VLP antibody titers similar to those induced by oral immunization, and significant protection in tumor protection experiments using HPV16-expressing C3 tumor cells. These results show that ivag immunization with live attenuated Salmonella expressing HPV16 antigens modulates the local mucosal gene expression pattern into a transient proinflammatory profile, elicits strong systemic and mucosal immunity against HPV16, and confers protection against HPV16 tumor cells subcutaneously implanted in mice. Examination of the efficacy with which ivag HPV16E7E6 Salmonella induces regression of tumors located in cervicovaginal tissue is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332214      PMCID: PMC2346685          DOI: 10.1128/IAI.01484-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  70 in total

Review 1.  How intracellular bacteria survive: surface modifications that promote resistance to host innate immune responses.

Authors:  R K Ernst; T Guina; S I Miller
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

2.  L1-specific protection from tumor challenge elicited by HPV16 virus-like particles.

Authors:  M L De Bruijn; H L Greenstone; H Vermeulen; C J Melief; D R Lowy; J T Schiller; W M Kast
Journal:  Virology       Date:  1998-10-25       Impact factor: 3.616

3.  Gene expression response of the rat small intestine following oral Salmonella infection.

Authors:  Wendy Rodenburg; Ingeborg M J Bovee-Oudenhoven; Evelien Kramer; Roelof van der Meer; Jaap Keijer
Journal:  Physiol Genomics       Date:  2007-03-20       Impact factor: 3.107

4.  Tumor-targeted Salmonella as a novel anticancer vector.

Authors:  J M Pawelek; K B Low; D Bermudes
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

5.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

Authors:  Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford
Journal:  Int J Cancer       Date:  2007-08-01       Impact factor: 7.396

7.  Human papillomavirus infection in women infected with the human immunodeficiency virus.

Authors:  X W Sun; L Kuhn; T V Ellerbrock; M A Chiasson; T J Bush; T C Wright
Journal:  N Engl J Med       Date:  1997-11-06       Impact factor: 91.245

Review 8.  HPV vaccines: the beginning of the end for cervical cancer.

Authors:  Graham R Leggatt; Ian H Frazer
Journal:  Curr Opin Immunol       Date:  2007-02-12       Impact factor: 7.486

9.  Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression.

Authors:  S L Giannini; W Al-Saleh; H Piron; N Jacobs; J Doyen; J Boniver; P Delvenne
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

10.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Authors:  Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

View more
  19 in total

Review 1.  Cancer immunotherapy: moving forward with peptide T cell vaccines.

Authors:  Takumi Kumai; Aaron Fan; Yasuaki Harabuchi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2017-07-19       Impact factor: 7.486

Review 2.  Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.

Authors:  Mevyn Nizard; Mariana O Diniz; Helene Roussel; Thi Tran; Luis Cs Ferreira; Cecile Badoual; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Sustained delivery of commensal bacteria from pod-intravaginal rings.

Authors:  Manjula Gunawardana; Madeline Mullen; Jennifer Yoo; Paul Webster; John A Moss; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

Review 4.  New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.

Authors:  Elizabeth D Gersch; Lutz Gissmann; Robert L Garcea
Journal:  Antivir Ther       Date:  2011-11-07

5.  Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.

Authors:  Jia-Zi Meng; Yu-Jun Dong; He Huang; Shuang Li; Yi Zhong; Shu-Lin Liu; Yue-Dan Wang
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

6.  Flagellin from recombinant attenuated Salmonella enterica serovar Typhimurium reveals a fundamental role in chicken innate immunity.

Authors:  Zhiming Pan; Qiuxia Cong; Shizhong Geng; Qiang Fang; Xilong Kang; Meng You; Xinan Jiao
Journal:  Clin Vaccine Immunol       Date:  2012-01-11

7.  Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.

Authors:  Zoe Hunter; Ebenezer Tumban; Agnieszka Dziduszko; Bryce Chackerian
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

Review 8.  Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment.

Authors:  Vafa Shahabi; Paulo C Maciag; Sandra Rivera; Anu Wallecha
Journal:  Bioeng Bugs       Date:  2010-01-04

9.  Oral immunization with recombinant lactobacillus plantarum induces a protective immune response in mice with Lyme disease.

Authors:  Beatriz del Rio; Raymond J Dattwyler; Miguel Aroso; Vera Neves; Luciana Meirelles; Jos F M L Seegers; Maria Gomes-Solecki
Journal:  Clin Vaccine Immunol       Date:  2008-07-16

Review 10.  Targeted Agents in Cervical Cancer: Beyond Bevacizumab.

Authors:  Gloria Marquina; Aranzazu Manzano; Antonio Casado
Journal:  Curr Oncol Rep       Date:  2018-04-02       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.